The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy

Tiziana Crepaldi,Simona Gallo,Paolo Maria Comoglio
DOI: https://doi.org/10.3390/ph17040448
IF: 4.6
2024-03-31
Pharmaceuticals
Abstract:The discovery and subsequent research on the MET oncogene's role in cancer onset and progression have illuminated crucial insights into the molecular mechanisms driving malignancy. The identification of MET as the hepatocyte growth factor (HGF) receptor has paved the path for characterizing the MET tyrosine kinase activation mechanism and its downstream signaling cascade. Over the past thirty years, research has established the importance of HGF/MET signaling in normal cellular processes, such as cell dissociation, migration, proliferation, and cell survival. Notably, genetic alterations that lead to the continuous activation of MET, known as constitutive activation, have been identified as oncogenic drivers in various cancers. The genetic lesions affecting MET, such as exon skipping, gene amplification, and gene rearrangements, provide valuable targets for therapeutic intervention. Moreover, the implications of MET as a resistance mechanism to targeted therapies emphasize the need for combination treatments that include MET inhibitors. The intriguing "flare effect" phenomenon, wherein MET inhibition can lead to post-treatment increases in cancer cell proliferation, underscores the dynamic nature of cancer therapeutics. In human tumors, increased protein expression often occurs without gene amplification. Various mechanisms may cause an overexpression: transcriptional upregulation induced by other oncogenes; environmental factors (such as hypoxia or radiation); or substances produced by the reactive stroma, such as inflammatory cytokines, pro-angiogenic factors, and even HGF itself. In conclusion, the journey to understanding MET's involvement in cancer onset and progression over the past three decades has not only deepened our knowledge, but has also paved the way for innovative therapeutic strategies. Selective pharmacological inactivation of MET stands as a promising avenue for achieving cancer remission, particularly in cases where MET alterations are the primary drivers of malignancy.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
The paper primarily explores the role of the MET oncogene in the occurrence and development of malignant tumors, as well as therapeutic strategies targeting MET. Below is a summary of the main issues the paper attempts to address: ### Issues the Paper Attempts to Address 1. **Understanding the function of the MET oncogene and its role in cancer**: - Investigate the mechanism of MET as a receptor for hepatocyte growth factor (HGF). - Explore the function of the MET signaling pathway in normal cellular processes, such as cell dissociation, migration, proliferation, and survival. 2. **Exploring how genetic variations related to MET drive the occurrence and development of malignant tumors**: - Analyze the types of genetic variations that lead to sustained activation of MET, including exon skipping, gene amplification, and gene rearrangement. - Discuss how these variations become oncogenic drivers in various cancers and promote the invasive and metastatic characteristics of tumors. 3. **Evaluating the role of MET in cancer treatment resistance**: - Describe the importance of MET as a mechanism of treatment resistance, especially in targeted therapies. - Explore the potential of combining MET inhibitors with other therapies to overcome treatment resistance. 4. **Discussing the phenomenon of MET protein overexpression**: - Explain the observation of MET protein overexpression in human tumors without gene amplification. - Explore different mechanisms that may lead to MET overexpression, such as transcriptional upregulation by other oncogenes, environmental factors, or substances produced by reactive stroma. 5. **Proposing innovative therapeutic strategies targeting MET**: - Introduce selective pharmacological inactivation of MET as a potential approach to achieve cancer remission, particularly when MET variation is the primary oncogenic driver. - Discuss the development of MET-targeted therapies, including tyrosine kinase inhibitors (TKIs), antibodies, and antibody-drug conjugates (ADCs). ### Conclusion Through three decades of research on the MET oncogene, we have not only deepened our understanding of its role in cancer occurrence and development but also provided a theoretical foundation for developing new therapeutic methods. Specifically, therapeutic strategies targeting MET show potential in effectively controlling cancer in certain specific cases. Additionally, the research reveals cross-talk between the MET signaling pathway and other receptors, which helps explain the mechanisms of cancer cell survival and growth, as well as their resistance to drugs.